
Spyglass Pharma, Inc. (NASDAQ:SGP – Free Report) – HC Wainwright cut their FY2026 earnings estimates for shares of Spyglass Pharma in a research note issued on Thursday, November 12th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($2.76) per share for the year, down from their previous forecast of ($2.52). HC Wainwright currently has a “Buy” rating and a $43.00 target price on the stock. The consensus estimate for Spyglass Pharma’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2026 earnings at ($0.75) EPS, Q1 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.64) EPS.
A number of other equities analysts also recently commented on SGP. UBS Group reaffirmed a “buy” rating on shares of Spyglass Pharma in a research note on Monday, October 5th. Stifel Nicolaus lifted their price objective on Spyglass Pharma from $42.00 to $44.00 and gave the company a “buy” rating in a research note on Friday. Citigroup raised their price target on Spyglass Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen upgraded shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Finally, Weiss Ratings upgraded shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.83.
Spyglass Pharma Price Performance
SGP opened at $32.88 on Monday. Spyglass Pharma has a 1-year low of $17.06 and a 1-year high of $39.92. The firm has a market capitalization of $1.10 billion and a price-to-earnings ratio of -4.25. The company’s 50 day simple moving average is $28.78 and its two-hundred day simple moving average is $24.83.
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.07).
Institutional Trading of Spyglass Pharma
Several hedge funds and other institutional investors have recently bought and sold shares of SGP. First Light Asset Management LLC purchased a new position in shares of Spyglass Pharma during the 1st quarter worth $9,716,000. Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma during the 1st quarter worth about $6,478,000. Monashee Investment Management LLC purchased a new position in shares of Spyglass Pharma during the 1st quarter worth about $2,461,000. Bank of America Corp DE acquired a new position in Spyglass Pharma during the first quarter worth approximately $726,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Spyglass Pharma in the second quarter valued at $533,000.
Spyglass Pharma Company Profile
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
Read More
- Five stocks we like better than Spyglass Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
